Zimmer Biomet Holdings (ZBH) AI Stock Analysis

Zimmer Biomet Holdings

(BMV:ZBH)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong cash generationImproving operating and free cash flow indicates that Zimmer Biomet is converting sales and earnings into internally generated funding. This supports investment in products and commercial capabilities, strengthens financial resilience, and provides flexibility for capital returns or strategic uses.

Negative Factors

Margin compressionRecent gross and operating margin declines show that investments in the U.S. commercial organization and higher manufacturing costs are weighing on profitability. If these costs persist, they could limit earnings conversion and reduce the financial benefit of otherwise steady revenue growth.

Zimmer Biomet Holdings (ZBH) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 18.03B
Dividend Yield: 1.08%
Average Volume (3M): 91
Price to Earnings (P/E): 22.9
Beta (1Y): 0.05
Revenue Growth: -1.19%
EPS Growth: -8.85%
Country: Mexico
Employees: 17,000
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Zimmer Biomet Holdings Business Overview & Revenue Model

Company Description

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products...

Zimmer Biomet Holdings Earnings Call Summary

Earnings Call Date:Aug 04, 2026(Q2-2026)|% Change Since:1.26%|Next Earnings Date:Nov 03, 2026

Earnings Call SentimentPositive

The call conveyed multiple strong operational and financial positives — revenue beat, raised guidance, robust cash generation, rapid technology and hip product adoption, successful Paragon integration and a sizable buyback — while acknowledging near-term headwinds including margin pressure from investment and manufacturing costs, pricing erosion risk, weakness in knees and China, and some supply constraints. Management framed 2026 as a transitional year with confidence that investments and go-to-market changes will improve execution and performance into 2027.

Positive Updates

Revenue Beat and Organic Growth

Second quarter net sales of $2.177 billion, +4.8% reported and +4.0% organic constant currency growth; U.S. organic growth +4.6% and international +3.1%.

Negative Updates

Knee Performance Weakness

Knees up only +0.1% for the quarter with U.S. knee growth +1.4% offset by international knee decline -1.5%, heavily impacted by weakness in China and core emerging markets.

Company Guidance

Zimmer Biomet raised its 2026 outlook, now forecasting full‑year organic constant‑currency revenue growth of 2.25%–3.25% (up from 1%–3%) and reported sales growth of 3.9%–4.9% (prior 2.5%–4.5%), with foreign exchange ~+50 bps to full‑year revenue (but ~‑50 bps headwind in Q3) and Paragon 28 now expected to contribute ~110 bps to reported sales (vs ~100 bps prior); the company assumes up to 100 bps of pricing erosion, increased adjusted EPS guidance to $8.47–$8.59 (from $8.40–$8.55), expects gross margin around 71% and operating margins to decline a little more than 50 bps (Q3 operating margin slightly down sequentially), anticipates net interest/other non‑operating expense of ~$295M and an adjusted tax rate of 18%, plans up to $1.0B of share repurchases (up $250M) leaving ~193M fully diluted shares, and continues to target free cash flow growth of 9%–11%.

Zimmer Biomet Holdings Risk Analysis

Zimmer Biomet Holdings disclosed 32 risk factors in its most recent earnings report. Zimmer Biomet Holdings reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Zimmer Biomet Holdings Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:ZBH against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GMED	87Outperform	$10.48B	19.66	11.59%	―	19.74%	51.10%
MDT	74Outperform	$123.49B	23.60	10.60%	2.96%	9.77%	12.28%
SNN	74Outperform	$12.42B	19.52	12.25%	2.67%	5.26%	31.02%
BVS	71Outperform	$1.12B	16.59	28.39%	―	3.14%	―
SYK	71Outperform	$111.95B	30.88	15.61%	1.21%	7.87%	22.82%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

MX:ZBH and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:ZBH	Zimmer Biomet Holdings	1623.99	-117.25	-6.73%
MDT	Medtronic	96.54	9.23	10.58%
SNN	Smith & Nephew Snats	29.70	-6.13	-17.11%
SYK	Stryker Corp	291.86	-62.38	-17.61%
GMED	Globus Medical	78.05	16.85	27.53%
BVS	Bioventus, Inc.	13.32	6.76	103.13%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Zimmer Biomet Holdings AI Stock Analysis